RxDoctor Payments Data

Jefferson Miley, MD

Vascular Neurology · Austin, TXNPI 1922292259

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Penumbra, Inc. accounts for 60.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $17,687 and has fallen 94.2% since, to $1,028 in 2025. Among vascular neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,138in general payments, 2019–2025

Across 124 payments — averaging $226.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$17K
  • Medtronic$5K
  • Abbott$2K
  • Microvention, Inc.$2K
  • Imperative Care, Inc$631
  • Johnson & Johnson$402
  • plus $716 from 7 others

What the payments were for

  • Consulting fees$2,0007%
  • Speaking & faculty fees$14,77553%
  • Travel & lodging$2,0167%
  • Food & beverage$9,34733%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,138 in reported general payments places this provider in the 90th percentile of 76 vascular neurology providers in Texas.

See all vascular neurology providers in Texas

Medicare billing

Part B allowed, 2024
$77,220
Medicare patients
137
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam14$261
ClopidogrelClopidogrel Bisulfate23$251

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →